This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab At University Of Texas At San Antonio

Headline of release should read: Threshold Pharmaceuticals Announces Initiation of Clinical Trial Evaluating TH-302 in Combination with Bevacizumab at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio (sted Threshold Pharmaceuticals Announces Initiation of Clinical Trial Evaluating TH-302 in Combination with Bevacizumab at University of Texas at San Antonio).

Facility in first, second and third graphs should read: Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio (sted University of Texas at San Antonio).

The corrected release reads:

THRESHOLD PHARMACEUTICALS ANNOUNCES INITIATION OF CLINICAL TRIAL EVALUATING TH-302 IN COMBINATION WITH BEVACIZUMAB AT THE CANCER THERAPY & RESEARCH CENTER AT THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma. Bevacizumab, marketed by Roche under the brand name Avastin ®, is a recombinant humanized monoclonal antibody that affects tumor vasculature which among its several approved indications is used to treat glioblastoma in patients whose cancer has progressed after prior treatment. Published studies have shown that treatment with Avastin increases the extent of hypoxia within the tumor. TH-302 is a novel small molecule hypoxia-targeted prodrug that is selectively activated by the low oxygen conditions believed to be induced in tumors by antiangiogenic therapies such as Avastin ®. With data from over 500 patients to date, TH-302 is currently being evaluated in a controlled Phase 2 clinical trial in patients with advanced pancreatic cancer, with a planned pivotal Phase 3 clinical trial in patients with soft tissue sarcoma expected to commence in the 3 rd quarter of this year.

"We are excited to evaluate TH-302 for the treatment of high grade brain tumors and to further explore the role of tumor hypoxia as a potential target in the treatment of this disease,” said Andrew Brenner, M.D., Ph.D., a neuro-oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and principal investigator for the trial. “While some success has been seen with drugs that target the tumor blood supply, patients ultimately relapse and there is increasing evidence that tumor hypoxia may be contributing to that treatment failure”, Dr. Brenner said. "In addition to establishing the safety and preliminary efficacy of TH-302 in combination with bevacizumab, this will be the first clinical study with TH-302 that will directly measure tumor hypoxia in solid tumors and attempt to correlate that with response.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs